Target intelligence / Profile preview

DnaJ heat shock protein family member A3 (DNAJA3)

Target
DNAJA3
Molecular classification
Heat shock protein, Molecular chaperone, DNAJ/Hsp40 family, Co-chaperone, Mitochondrial protein
01

Overview

DnaJ heat shock protein family member A3 (DNAJA3, also known as Tid1) is a mitochondrial molecular chaperone of the DNAJ/Hsp40 family. DNAJA3 partners with Hsp70 chaperones to regulate protein folding, degradation, and assembly of multiprotein complexes—critical for mitochondrial biogenesis and maintenance of membrane potential and DNA integrity. It exists as two isoforms with distinct apoptotic effects: one promotes apoptosis through cytochrome C release, while the other inhibits apoptosis. DNAJA3 interacts with key cancer-related proteins such as p53 and ErbB2, functioning as a tumor suppressor, and may modulate cellular proliferation and survival signals. Disease associations include various cancers, neurodegenerative diseases, and inflammatory conditions. The protein is crucial for proper mitochondrial and cellular homeostasis, with its expression and function influencing disease outcomes and therapeutic strategies.

Other names
Tid1TID1HCA57hTid-1Tid1-STid1-LDNJA3_HUMANtumorous imaginal disc 1tumorous imaginal discs protein Tid56 homologDnaJ protein Tid-1
02

Mechanism of action

Promotion of apoptosis via cytochrome C release and caspase activation; Tumor suppression by interaction with p53 and downregulation of oncogenic ErbB2 receptors; Regulation of EGFR/AKT signaling pathways; Support of protein folding in mitochondria

03

Biological functions

Protein foldingProtein degradationComplex assemblyTumor suppressionCell proliferationApoptosisCell deathCell survivalCellular homeostasisMitochondrial membrane potential maintenanceMitochondrial DNA integrityNeuromuscular junction development
04

Disease associations

Cancer (including breast, skin, colorectal, and head and neck cancers)Neurodegenerative diseases (e.g., Parkinson’s disease)Inflammatory diseases (e.g., psoriasis)Dilated cardiomyopathy
05

Safety considerations

Potential challenge due to dual isoform effects (pro-apoptotic vs anti-apoptotic)Altered expression may impact cell survival or trigger mitochondrial dysfunction; dysregulation could contribute to cancer progression or neurodegeneration
06

Interacting drugs

No direct drugs listed in provided sources; indirect association with cancer therapies targeting ErbB2/HER2 or p53 pathways
07

Biomarkers

DNAJA3 may serve as a biomarker for tumor suppression status, apoptotic signaling integrity, and mitochondrial function in cancer and neurodegenerative disorders

Beyond the preview

Go deeper on DnaJ heat shock protein family member A3 (DNAJA3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on DnaJ heat shock protein family member A3 (DNAJA3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call